Neue Biomarker beim Zervixkarzinom
作者： K. Kübler , C.M. Domröse , W. Kuhn
DOI: 10.1007/S00129-013-3292-X
关键词:
摘要: Die klassischen Prognosefaktoren des Zervixkarzinoms sind Tumorausdehnung, Tumormorphologie und Lymphknotenbefall. Biomarker erlauben eine zusatzliche Information uber die Tumorbiologie somit exaktere Prognose. endgultige Bewertung neuer ist aufgrund kontroverser Studienergebnisse noch nicht moglich. Ursachlich hier vor allem unterschiedliche Detektionsmethoden ohne einheitlichen Grenzwert heterogene Kollektive im Rahmen retrospektiver Analysen. Dies der Grund, dass bisher kein Eingang in klinische Praxis gefunden hat. Als aussichtsreiche Kandidaten erscheinen derzeit Uberexpression von VEGF COX-2 sowie Nachweis eines LOH („loss of heterozygosity“) auf 6p21.2 18q21.2. In fruhen Stadien wirkt sich zudem Lymphangiosis carcinomatosa prognostisch ungunstig aus. Zukunftig wird molekularen Charakterisierung, welche Komplexitat individuellen Tumorgeschehens Rechnung tragt, mittels Erstellung Genexpressionsprofilen mehr Raum gegeben werden.
springer.com
sci-hub.se 参考文章(35)
T. W. Park, K. Behrens, T. Löning, Histopathologische und molekulare Prognosefaktoren des Zervixkarzinoms Onkologe. ,vol. 12, pp. 869- 878 ,(2006) , 10.1007/S00761-006-1107-6
Chel Hun Choi, Sang Yong Song, Jung-Joo Choi, Young Ae Park, Heeseok Kang, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae, Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy BMC Cancer. ,vol. 8, pp. 295- 295 ,(2008) , 10.1186/1471-2407-8-295
Yoko Harima, Satoshi Sawada, Kenji Nagata, Mitsuharu Sougawa, Takeo Ohnishi, Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. International Journal of Cancer. ,vol. 96, pp. 286- 296 ,(2001) , 10.1002/IJC.1027
H. Pilch, S. Gunzel, U. Schaffer, B. Tanner, P. Brockerhoff, M. Maeurer, M. Hockel, G. Hommel, P. G. Knapstein, The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. International Journal of Gynecological Cancer. ,vol. 11, pp. 39- 48 ,(2001) , 10.1046/J.1525-1438.2001.011001039.X
D. Cantu De Leon, C. Lopez-Graniel, M. Frias Mendivil, G. Chanona Vilchis, C. Gomez, J. De La Garza Salazar, Significance of microvascular density (MVD) in cervical cancer recurrence. International Journal of Gynecological Cancer. ,vol. 13, pp. 856- 862 ,(2003) , 10.1111/J.1525-1438.2003.13399.X
Gregorio Delgado, Brian Bundy, Richard Zaino, Bernd-Uwe Sevin, William T. Creasman, Francis Major, Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology. ,vol. 38, pp. 352- 357 ,(1990) , 10.1016/0090-8258(90)90072-S
K.BM. LEE, J.M. LEE, C.Y. PARK, K.B. LEE, H.Y. CHO, S.Y. HA, What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. International Journal of Gynecological Cancer. ,vol. 16, pp. 1569- 1573 ,(2006) , 10.1111/J.1525-1438.2006.00628.X
Yong Bae Kim, Gwi Eon Kim, Hong Ryull Pyo, Nam Hoon Cho, Ki Chang Keum, Chang Geol Lee, Jinsil Seong, Chang Ok Suh, Tchan Kyu Park, Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix International Journal of Radiation Oncology*Biology*Physics. ,vol. 60, pp. 822- 829 ,(2004) , 10.1016/J.IJROBP.2004.04.030
William T Creasman, Matthew F Kohler, Is lymph vascular space involvement an independent prognostic factor in early cervical cancer Gynecologic Oncology. ,vol. 92, pp. 525- 529 ,(2004) , 10.1016/J.YGYNO.2003.11.020
Matthias W. Beckmann, , Peter Mallmann, Interdisciplinary S2k guideline on the diagnosis and treatment of cervical carcinoma. Journal of Cancer Research and Clinical Oncology. ,vol. 135, pp. 1197- 1206 ,(2009) , 10.1007/S00432-009-0560-1